Clinical trials Mayo Clinic in Rochester, Minnesota, Mayo Clinic in Jacksonville, Florida, and Mayo Clinic in Phoenix/Scottsdale, Arizona, are ranked among the Best Hospitals for cancer by U.S. News & World Report. Mayo Clinic in Rochester, Minnesota, ranks No. 1 for digestive disorders in the U.S. News & World Report Best Hospitals rankings. Mayo Clinic in Phoenix/Scottsdale, Arizona, and Mayo Clinic in Jacksonville, Florida, are ranked among the Best Hospitals for digestive disorders by U.S. News & World Report. In U.S. News & World Report’s regional analysis, Mayo Clinic Children’s is ranked No. 1 in Minnesota and No. 1 in the five-state Upper Midwest region, which includes Minnesota, Wisconsin, Iowa, North Dakota and South Dakota. Below are current clinical trials.2 studies in Colon and Rectal Surgery (open studies only). Filter this list of studies by location, status and more. Genomic and Environmental Basis of Imperforate Anus Rochester, Minn. The study aims are to develop a consent-based IRB proposal that will enroll newborns who have imperforate anus. The proposal will include permission for chart review and database information storage, to develop a database that will include MRN, imperforate anus phenotype, information on other congenital malformations, syndromic diagnosis if available, demographic information, and to develop a biobank of DNA and white blood cell samples from infants with imperforate anus. If patients are undergoing a skin biopsy for a medically indicated reason, cells will be requested. Imperforate Anus, also known as anal atresia, is a rare birth defect. Unable to pass stool through the gastrointestinal tract, this condition can result in death of the newborn and emergency surgery is required once discovered. More than two thirds of affected infants have other birth defects that include other parts of the gastrointestinal tract, airway, heart, skeleton, kidneys, eyes, or ears. The exact prevalence of imperforate anus in the newborn population is unknown. Study Of Zanzalintinib In Combination With Immuno-Oncology Agents In Participants With Solid Tumors Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) in participants with advanced solid tumors.In the Expansion Stage, the safety and efficacy of zanzalintinib as monotherapy and in combination therapy will be further evaluated in tumor-specific Expansion Cohorts. Request an appointment Expertise & rankingsResearch Aug. 30, 2025 Share on: FacebookTwitter Colon and Rectal SurgeryDepartmenthomeSectionsOverviewTests & proceduresConditions treatedDoctorsExpertise & rankingsClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals Research: It's all about patients Show transcript for video Research: It's all about patients [MUSIC PLAYING] Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to advance how we can best help the patient, how to make sure the patient comes first in care. So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes right — and let's say it's helpful or beneficial — then brought on as a standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to put it in its own spotlight. SectionsRequest an AppointmentOverviewTests & proceduresConditions treatedDoctorsExpertise & rankingsClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals ORG-20310670 Medical Departments & Centers Colon and Rectal Surgery